<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505127</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-438/CCT-401</org_study_id>
    <secondary_id>U1111-1126-5073</secondary_id>
    <secondary_id>JapicCTI-111722</secondary_id>
    <nct_id>NCT01505127</nct_id>
  </id_info>
  <brief_title>Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the First Line Eradication of H.Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy of triple therapy with TAK-438,
      Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to
      triple therapy with Lansoprazole, Amoxicillin and Clarithromycin in H. pylori-positive
      patients with scarred gastric or duodenal ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate 4 weeks after completion of first-line therapy</measure>
    <time_frame>4-weeks post-dose (first-line therapy)</time_frame>
    <description>The participants are judged to be H. pylori-negative or H. pylori-positive based on the 13C-Urea Breath Test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>H. pylori eradication rate 4 weeks after completion of second-line therapy</measure>
    <time_frame>4-weeks post-dose (second-line therapy)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>H. Pylori Infection</condition>
  <arm_group>
    <arm_group_label>TAK-438 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-438 20 mg, tablets, orally, twice daily for 1 week
Lansoprazole placebo-matching capsules, orally, twice daily for 1 week
Amoxicillin 750 mg, capsules, orally, twice daily for 1 week
Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-438 placebo-matching tablets, orally, twice daily for 1 week
Lansoprazole 30 mg, capsules, orally, twice daily for 1 week
Amoxicillin 750 mg, capsules, orally, twice daily for 1 week
Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-438</intervention_name>
    <arm_group_label>TAK-438 20 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <arm_group_label>Lansoprazole 30 mg BID</arm_group_label>
    <other_name>AG-1749</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <arm_group_label>TAK-438 20 mg BID</arm_group_label>
    <arm_group_label>Lansoprazole 30 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <arm_group_label>TAK-438 20 mg BID</arm_group_label>
    <arm_group_label>Lansoprazole 30 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must be H. pylori-positive patients at baseline (Visit 1)

          2. Participants must be endoscopically confirmed to have scarred gastric ulcer or
             duodenal ulcer at baseline (Visit 1).

             However, if a history of ulcers is confirmed by the medical interview or previous
             medical record, Participants whose gastric ulcer scar or duodenal ulcer scar has
             disappeared may be included in the study.

          3. Outpatient (including inpatient for examination)

        Exclusion Criteria:

          1. Participants who have received H.pylori eradication treatment

          2. Participants who have either acute upper gastrointestinal bleeding, gastric ulcer
             [mucosal defect (with white coating including clot adherence) of 3 mm or larger in
             size], duodenal ulcer [mucosal defect (with white coating including clot adherence) of
             3 mm or larger in size], acute gastric mucosal lesion (AGML), or acute duodenal
             mucosal lesion (ADML) on endoscopic examination at baseline (Visit 1).

             However, participants with gastric erosion or duodenal erosion may be included in the
             study.

          3. Participants who have received or who are scheduled to undergo surgery which affects
             gastric acid secretion (ex, resection of upper gastrointestinal tract, vagotomy, etc)

          4. Participants who cannot be treated with medicinal treatment (ex, perforation, pyloric
             stenosis or large hemorrhage, etc)

          5. Participants with a previous or current history of Zollinger-Ellison syndrome, or
             other gastric acid hypersecretion disorders

          6. Participants with hepatic or renal impairment receiving treatment with colchicines

          7. Participants who have a history of hypersensitivity or allergy to TAK-438 (including
             its excipients), PPIs, penicillin antibiotics, macrolide antibiotics, or
             antitrichomonal agents

          8. Participants with infectious mononucleosis

          9. Participants with an organic disease of the brain or spinal cord
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Abiko-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ishikari-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marugame-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ebina-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yatsushiro-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita-shi</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumagaya-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kokubunji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishi-tokyo-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>November 2, 2013</last_update_submitted>
  <last_update_submitted_qc>November 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

